CBIO vs SPGI · $491.3M cap vs P/E 27, rev $15.34B
Crescent Biopharma, Inc. (CBIO) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
CBIO does not have a complete income-statement cache yet.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
CBIO currently screens at market cap $491.3M. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the CBIO and SPGI stock pages for the full models.
Not investment advice.